pharma · Locally advanced or metastatic urothelial cancer · Nectin-4 Expressing Advanced Malignancies. · BCYC
BICYCLE THERAPEUTICS
BICYCLE THERAPEUTICS is a pharma organization headquartered in Cambridge, GB. It trades on NYSE under ticker BCYC. Primary therapeutic focus areas include Locally advanced or metastatic urothelial cancer, Nectin-4 Expres
Cambridge, GB HQ
2009 Founded
282 Employees
Public company Type
BCYC · NYSE Ticker
Company details
- Status
- Public
- HQ
- Cambridge, GB
- Founded
- 2009
- Employees
- 282
- Programs
- 8
- Drugs
- 15
- Patents
- 57
BT8009-230
Phase 3 · small molecule · Locally advanced or metastatic urothelial cancer
BT8009-230 for Locally advanced or metastatic urothelial cancer is a Phase 3 program (small_molecule) at BICYCLE THERAPEUTICS with 1 ClinicalTrials.gov record(s).
Internal code BT8009-230
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- BICYCLE THERAPEUTICS
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Locally advanced or metastatic urothelial cancer
- Status
- active
- Trials
- 1